HCPCS Level II code Q5128 designates the biosimilar ranibizumab-eqrn (Cimerli), 0.1 mg, for intravitreal injection. This code matters nationally as biosimilar retinal biologics expand treatment options for retinal vascular diseases and age-related macular degeneration, potentially affecting access, utilization, and payer coverage strategies across commercial and public plans. Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will find a concise overview of clinical context for intravitreal ranibizumab biosimilars, typical sites of service (ophthalmology clinics, ambulatory surgery centers, hospital outpatient departments), and the implications for billing workflows. The publication covers benchmarks for coverage and reimbursement patterns, payer policy considerations, common billing modifiers and coding practice notes, and areas where policy updates may influence provider billing and payer adjudication. Where input data are incomplete, the text notes missing items as "Data not available in the input." The goal is to provide clinicians, billing professionals, and policy analysts a clear, national-level brief on coding and operational considerations tied to Q5128 without making clinical recommendations.